Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYeung‐Chul MunSPSungho ParkSLSemin Lee

Discussion

Loading...

Member takes

Overview

Prospective observational study reveals molecular response and treatment duration correlate with TFR success in chronic myeloid leukemia patients.

Key Points

  • To identify predictors for successful discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
  • Conducted a retrospective and prospective observational study
  • Analyzed CP-CML patients maintaining MR4.5 for at least 4 years
  • Monitored molecular response using RT-qPCR after TKI discontinuation
  • 71.1% of patients were on first-line tyrosine kinase inhibitors at discontinuation
  • TFR rates at 12, 24, and 48 months were 77.6%, 72.2%, and 70.3% respectively
  • Multivariate analysis linked molecular relapse to BCR::ABL1 halving time and duration of complete molecular response

Cite This Study

Mun et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e128https://doi.org/10.1182/blood-2025-2002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durable treatment-free remission in CML beyond clinical trials: Lessons from a large single-center real-world experience.2026
  2. 2Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia2026
  3. 3Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors2025
  4. 4Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study2026
  5. 5Molecular remission after tyrosine kinase inhibitor cessation in chronic myeloid leukemia (CML): A systematic review and meta-analysis.2026